Clinical trial
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
NCT00331851 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00331851 |
|---|---|
| Title | Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes |
| Official title | Liraglutide Effect and Action in Diabetes (LEAD-5): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride and Metformin Versus Glimepiride and Metformin Combination Therapy, and Versus Insulin Glargine Added to Glimepiride and Metformin… |
| Acronym | LEAD-5 |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes, Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | liraglutide, insulin glargine, metformin, glimepiride |
| Enrollment | 584 |
| Start date | May 1, 2006 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | May 31, 2006 |
| Last update posted | Jan 26, 2017 |
| Countries | Argentina, Austria, Brazil, Denmark, Finland, France, India, Italy, Netherlands, Norway, Philippines, Poland and 6 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: